Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Caplyta price, strengths & recalls

Brand of lumateperone (generic)

Pharmacies pay $1,717.21 for 30 capsules of Caplyta 42 mg capsule this week, and from $1,716.07 to $1,717.21 across its 3 priced strengths and forms. Its official label last changed on November 9, 2026.

Brand
Pharmacies pay$1,717.21for 30 capsules of 42 mg capsuleNo change in 4 weeks
Fair cash price
$1,985.29
Strengths
3
Makers
1
Updated
Nov 11

Caplyta price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
10.5 mg capsule Brand$57.22$1,716.52 / 30 capsulesNo change+4.7%
21 mg capsule Brand$57.20$1,716.07 / 30 capsulesNo change+4.8%
42 mg capsule Brand$57.24$1,717.21 / 30 capsulesNo change+4.9%

The lowest cost per capsule is 21 mg capsule at $57.20. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Caplyta vs generic lumateperone

There is no generic version of Caplyta on the market yet. Its last listed patent or exclusivity runs to December 10, 2040 - generics often follow, though court cases and settlements can move the date either way.

GenericLumateperone prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recallsNone on record

What did you pay for caplyta? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedNovember 9, 2026
Version28 of 13
EffectiveNov 5, 2026
Read the label

These highlights do not include all the information needed to use CAPLYTA safely and effectively. See full prescribing information for CAPLYTA. CAPLYTA® (lumateperone) capsules, for oral use Initial U.S. Approval: 2019

This drug has a boxed warning

WARNING:

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL

THOUGHTS AND BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)].

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.2)]. The safety and effectiveness of CAPLYTA have not been established in pediatric patients [see Use in Specific Populations (8.4)].

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA is not approved for the treatment of patients with dementia-related psychosis. (5.1)

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients. Closely monitor all antidepressant-treated patients for worsening and emergence of suicidal thoughts and behaviors. Safety and effectiveness of CAPLYTA have not been established in pediatric patients. (5.2, 8.4)

Recent major changes (as listed on the label)

Indications and Usage, adjunctive treatment of major depressive disorder (1)

| 11/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA209500 · Intra-Cellular
First approved
December 20, 2019 (7 years ago)
Latest approved change
April 24, 2026
Approved label
PDF, Apr 28, 2026
Generic makers
None on the market
Last patent listed
December 10, 2040
Exclusivity ends
April 24, 2029

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Caplyta questions

How much does caplyta cost without insurance?

Pharmacies pay about $1,717.21 for 30 capsules of caplyta 42 mg capsule ($57.24 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,985.29. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Caplyta?

Yes: lumateperone. Compare lumateperone prices.

Is caplyta in shortage?

No shortage is reported for caplyta right now. We check the national shortage list every day.

Has caplyta been recalled?

No recalls are on record for caplyta.

When did the caplyta label last change?

The official label was last updated on November 9, 2026 (version 28). See what changed.

Talk about caplyta

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.